Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate including tumor necrosis factor inhibitors, abatacept, tocilizumab, and rituximab. Clinical response to drugs varies widely between individuals. A part of this variability is...
Saved in:
Main Authors: | Claire I. Daïen, Jacques Morel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2014/386148 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01) -
South African Rheumatism and Arthritis Association 2024 guidelines for the use of biologic and targeted synthetic disease-modifying antirheumatic drugs
by: E van Duuren, et al.
Published: (2024-09-01) -
Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis
by: Yoshifumi Tada, et al.
Published: (2021-01-01) -
Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
by: Richard Conway, et al.
Published: (2021-01-01) -
Gold Finger: Metal Jewellery as a Disease Modifying Antirheumatic Therapy!
by: T. Hlaing, et al.
Published: (2009-01-01)